200 related articles for article (PubMed ID: 27853637)
1. Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8
Baumgaertner P; Costa Nunes C; Cachot A; Maby-El Hajjami H; Cagnon L; Braun M; Derré L; Rivals JP; Rimoldi D; Gnjatic S; Abed Maillard S; Marcos Mondéjar P; Protti MP; Romano E; Michielin O; Romero P; Speiser DE; Jandus C
Oncoimmunology; 2016; 5(10):e1216290. PubMed ID: 27853637
[TBL] [Abstract][Full Text] [Related]
2. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
Fourcade J; Kudela P; Andrade Filho PA; Janjic B; Land SR; Sander C; Krieg A; Donnenberg A; Shen H; Kirkwood JM; Zarour HM
J Immunother; 2008 Oct; 31(8):781-91. PubMed ID: 18779741
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
[TBL] [Abstract][Full Text] [Related]
4. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
[TBL] [Abstract][Full Text] [Related]
5. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.
Eikawa S; Kakimi K; Isobe M; Kuzushima K; Luescher I; Ohue Y; Ikeuchi K; Uenaka A; Nishikawa H; Udono H; Oka M; Nakayama E
Int J Cancer; 2013 Jan; 132(2):345-54. PubMed ID: 22729530
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Wada H; Isobe M; Kakimi K; Mizote Y; Eikawa S; Sato E; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Yamasaki M; Miyata H; Matsushita H; Udono H; Seto Y; Yamada K; Nishikawa H; Pan L; Venhaus R; Oka M; Doki Y; Nakayama E
J Immunother; 2014; 37(2):84-92. PubMed ID: 24509171
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
[TBL] [Abstract][Full Text] [Related]
9. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
Gnjatic S; Atanackovic D; Jäger E; Matsuo M; Selvakumar A; Altorki NK; Maki RG; Dupont B; Ritter G; Chen YT; Knuth A; Old LJ
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8862-7. PubMed ID: 12853579
[TBL] [Abstract][Full Text] [Related]
10. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
Khong HT; Yang JC; Topalian SL; Sherry RM; Mavroukakis SA; White DE; Rosenberg SA
J Immunother; 2004; 27(6):472-7. PubMed ID: 15534491
[TBL] [Abstract][Full Text] [Related]
11. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
13. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.
Tsuji T; Sabbatini P; Jungbluth AA; Ritter E; Pan L; Ritter G; Ferran L; Spriggs D; Salazar AM; Gnjatic S
Cancer Immunol Res; 2013 Nov; 1(5):340-50. PubMed ID: 24777970
[TBL] [Abstract][Full Text] [Related]
14. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
[TBL] [Abstract][Full Text] [Related]
15. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
[TBL] [Abstract][Full Text] [Related]
16. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
[TBL] [Abstract][Full Text] [Related]
17. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
[TBL] [Abstract][Full Text] [Related]
18. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
